The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy
Abstract
Minority U.S. populations are underrepresented in cancer clinical trials. This review appraises the impact of the disparity in clinical trial participation by minority patients in the current era of cancer immunotherapy. Enrollment on pivotal trials leading to U.S. regulatory approval of immune checkpoint inhibitors showed poor representation of minority ethnic groups. Specifically, we found that black patients constitute less than 4% of all patients enrolled across multiple trials that supported the approval of immune checkpoint inhibitors for the treatment of lung cancer. Similar underrepresentation was observed for trials conducted in renal cell carcinoma and other tumor types. Since efficacy of immunotherapy is only observed in a subset of patients, the use of predictive biomarkers to identify responders along with new strategies to expand the benefit to a larger subset of patients are current areas of active investigation. The inadequate representation of minority patients on immunotherapy clinical trials could perpetuate outcome disparity because the unique biology of the host and the tumors from this subpopulation is not accounted for as new treatment algorithms to guide optimal use of immunotherapy are developed for use in the real world.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Self-citationNivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Genomics is failing on diversity
Popejoy, A. B., & Fullerton, S. M. (2016) · Nature · doi:10.1038/538161a · Cited by 1,924
Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0013 · Cited by 1,784
Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33297-x · Cited by 1,408
Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review
Ford, J. G., Howerton, M. W., Lai, G. Y., Gary, T. L., Bolen, S., Gibbons, M. C., Tilburt, J., Baffi, C., Tanpitukpongse, T. P., Wilson, R. F., et al. (2008) · Cancer · doi:10.1002/cncr.23157 · Cited by 1,083
Are Racial and Ethnic Minorities Less Willing to Participate in Health Research?
Wendler, D., Kington, R., Madans, J., Wye, G. V., Christ-Schmidt, H., Pratt, L. A., Brawley, O. W., Gross, C. P., & Emanuel, E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0030019 · Cited by 854
Increasing Diversity in Clinical Trials: Overcoming Critical Barriers
Clark, L. T., Watkins, L., Piña, I. L., Elmer, M., Akinboboye, O., Gorham, M., Jamerson, B., McCullough, C., Pierre, C., Polis, A. B., et al. (2019) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2018.11.002 · Cited by 731
Diversity in clinical and biomedical research: a promise yet to be fulfilled
Oh, S. S., Galanter, J., Thakur, N., Pino-Yanes, M., Barcelo, N. E., White, M. J., de Bruin, D. M., Greenblatt, R. M., Bibbins-Domingo, K., Wu, A. H. B., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001918 · Cited by 585
Larkin, J., Minor, D., D'Angelo, S., Neyns, B., Smylie, M., Miller, W. H., Gutzmer, R., Linette, G., Chmielowski, B., Lao, C. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.8023 · Cited by 516
Kim, E. S., Bruinooge, S. S., Roberts, S., Ison, G., Lin, N. U., Gore, L., Uldrick, T. S., Lichtman, S. M., Roach, N., Beaver, J. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7916 · Cited by 485
Chen, M. S., Lara, P. N., Dang, J. H. T., Paterniti, D. A., & Kelly, K. (2014) · Cancer · doi:10.1002/cncr.28575 · Cited by 472
Transancestral mapping and genetic load in systemic lupus erythematosus
Langefeld, C. D., Ainsworth, H. C., Graham, D. S. C., Kelly, J. A., Comeau, M. E., Marion, M. C., Howard, T. D., Ramos, P. S., Croker, J. A., Morris, D. L., et al. (2017) · Nature Communications · doi:10.1038/ncomms16021 · Cited by 420
Real-world Data for Clinical Evidence Generation in Oncology
Khozin, S., Blumenthal, G. M., & Pazdur, R. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx187 · Cited by 346
Geller, S. E., Koch, A. R., Roesch, P., Filut, A., Hallgren, E., & Carnes, M. (2018) · Academic Medicine · doi:10.1097/acm.0000000000002027 · Cited by 314
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors
Bajaj, G., Wang, X., Agrawal, S., Gupta, M., Roy, A., & Feng, Y. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12143 · Cited by 264
Lack of reduction in racial disparities in cancer‐specific mortality over a 20‐year period
Aizer, A. A., Wilhite, T. J., Chen, M., Graham, P. L., Choueiri, T. K., Hoffman, K. E., Martin, N. E., Trinh, Q., Hu, J. C., & Nguyen, P. L. (2014) · Cancer · doi:10.1002/cncr.28617 · Cited by 252
Inclusion of minorities and women in cancer clinical trials, a decade later: have we improved?
Kwiatkowski, K., Coe, K., Bailar, J. C., & Swanson, G. M. (2013) · Cancer · doi:10.1002/cncr.28168 · Cited by 240
Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas
Lin, S. J., Gagnon-Bartsch, J. A., Tan, I. B., Earle, S., Ruff, L., Pettinger, K., Ylstra, B., van Grieken, N., Rha, S. Y., Chung, H. C., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-308252 · Cited by 229
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications
Kuriakose, A., Chirmule, N., & Nair, P. (2016) · Journal of Immunology Research · doi:10.1155/2016/1298473 · Cited by 227
Martin, D. N., Boersma, B. J., Yi, M., Reimers, M., Howe, T. M., Yfantis, H. G., Tsai, Y. C., Williams, E. H., Lee, D. H., Stephens, R. M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004531 · Cited by 223
The Tuskegee Legacy Project: Willingness of Minorities to Participate in Biomedical Research
Katz, R. V., Kegeles, S. S., Kressin, N. R., Green, B. L., Wang, M. Q., James, S. A., Russell, S. L., & Claudio, C. (2006) · Journal of Health Care for the Poor and Underserved · doi:10.1353/hpu.2006.0126 · Cited by 218
McLaren, P. J., Coulonges, C., Bartha, I., Lenz, T. L., Deutsch, A. J., Bashirova, A., Buchbinder, S., Carrington, M. N., Cossarizza, A., Dalmau, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1514867112 · Cited by 182
The impact of host genetic variation on infection with HIV-1
McLaren, P. J., & Carrington, M. N. (2015) · Nature Immunology · doi:10.1038/ni.3147 · Cited by 171
Ahamadi, M., Freshwater, T., Prohn, M., Li, C. H., de Alwis, D., de Greef, R., Elassaiss‐Schaap, J., Kondic, A. G., & Stone, J. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12139 · Cited by 165
Analysis of Racial/Ethnic Representation in Select Basic and Applied Cancer Research Studies
Guerrero, S., López-Cortés, A., Indacochea, A., García-Cárdenas, J. M., Zambrano, A. K., Cabrera-Andrade, A., Guevara-Ramírez, P., González, D. A., Leone, P. E., & Paz-y-Miño, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-32264-x · Cited by 163
Trends in National Institutes of Health Funding for Clinical Trials Registered in ClinicalTrials.gov
Ehrhardt, S., Appel, L. J., & Meinert, C. L. (2015) · JAMA · doi:10.1001/jama.2015.12206 · Cited by 160
Ethnic differences in drug metabolism and toxicity from chemotherapy
Phan, V. H., Moore, M. M., McLachlan, A. J., Piquette‐Miller, M., Xu, H., & Clarke, S. J. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902800153 · Cited by 129
Donia, M., Kimper-Karl, M. L., Høyer, K. L., Bastholt, L., Schmidt, H., & Svane, I. M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.017 · Cited by 105
Enrolling Minority and Underserved Populations in Cancer Clinical Research
Wallington, S. F., Dash, C., Sheppard, V. B., Goode, T. D., Oppong, B. A., Dodson, E., Hamilton, R. N., & Adams-Campbell, L. L. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.07.036 · Cited by 87
Kinseth, M. A., Jia, Z., Rahmatpanah, F. B., Sawyers, A., Sutton, M., Wang‐Rodriguez, J., Mercola, D., & McGuire, K. L. (2013) · International Journal of Cancer · doi:10.1002/ijc.28326 · Cited by 85
Krishnan, B., Rose, T. L., Kardos, J., Milowsky, M. I., & Kim, W. Y. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0005 · Cited by 75
Kverneland, A. H., Enevold, C., Donia, M., Bastholt, L., Svane, I. M., & Nielsen, C. H. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1424674 · Cited by 61
Immunotherapy in the Asiatic population: any differences from Caucasian population?
Peng, L.-X., & Wu, Y.-L. L. C. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.106 · Cited by 61
Vickers, S. M., & Fouad, M. N. (2014) · Cancer · doi:10.1002/cncr.28569 · Cited by 54
Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study
Greenberg, A. J., Philip, S., Paner, A., Velinova, S., Badros, A. Z., Catchatourian, R., Ketterling, R. P., Kyle, R. A., Kumar, S. K., Vachon, C. M., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2014.91 · Cited by 45
Smith, J. P., Wang, S., Nadella, S., Jablonski, S. A., & Weiner, L. M. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2077-9 · Cited by 39
Paulucci, D. J., Sfakianos, J. P., Skanderup, A. J., Kan, K. M., Tsao, C., Galsky, M. D., Hakimi, A. A., & Badani, K. K. (2016) · Oncotarget · doi:10.18632/oncotarget.14122 · Cited by 29
Ibraheem, A. F., & Polite, B. N. (2017) · Cancer · doi:10.1002/cncr.31073 · Cited by 23
Incentivizing Recruitment and Retention to Address Enrollment Challenges in Clinical Research
Dickert, N. W., Halpern, S. D., & Butler, J. (2013) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000176 · Cited by 14
Marchioni, M., Harmouch, S. S., Nazzani, S., Bandini, M., Preißer, F., Tian, Z., Kapoor, A., Cindolo, L., Briganti, A., Shariat, S. F., et al. (2018) · Cancer Epidemiology · doi:10.1016/j.canep.2018.04.006 · Cited by 14
Cited by
Cancer statistics for African American/Black People 2022
Giaquinto, A. N., Miller, K. D., Tossas, K. Y., Winn, R. A., Jemal, A., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21718 · Cited by 574
Priorities for cancer research in low- and middle-income countries: a global perspective
Pramesh, C. S., Badwe, R. A., Bhoo-Pathy, N., Booth, C. M., Chinnaswamy, G., Dare, A. J., de Andrade, V. P., Hunter, D. J., Gopal, S., Gospodarowicz, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01738-x · Cited by 434
Race/ethnicity reporting and representation in US clinical trials: A cohort study
Turner, B. E., Steinberg, J. R., Weeks, B. T., Rodriguez, F., & Cullen, M. R. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100252 · Cited by 395
Inan, O. T., Tenaerts, P., Prindiville, S. A., Reynolds, H. R., Dizon, D. S., Cooper-Arnold, K., Turakhia, M., Pletcher, M. J., Preston, K. L., Krumholz, H. M., et al. (2020) · npj Digital Medicine · doi:10.1038/s41746-020-0302-y · Cited by 329
“For example, Black Americans represented only 2.5% and 4% of enrollees in trials involving cardiology or cancer immunotherapy 24,25 .”
BackgroundInfluentialNassar, A. H., Adib, E., Abou Alaiwi, S., El Zarif, T., Groha, S., Akl, E. W., Nuzzo, P. V., Mouhieddine, T. H., Perea-Chamblee, T., Taraszka, K., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.022 · Cited by 121
Metadata
- Authors
- Nazha, B., Mishra, M., Pentz, R., & Owonikoko, T. K.
- Venue
- American Society of Clinical Oncology Educational Book
- Published
- 2019-05
- Volume
- 39
- Issue
- 39
- Pages
- 3-10
- ISSN
- 1548-8748 (ISSN-L)
- 1548-8756
- OpenAlex
- W2946614049
- Cited by
- 257
- References
- 46
- FWCI
- 26.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.